Radiation Research, Vol. 188, No. 2 (August 2017), pp. 156-168 (13 pages) Rapid clinical triage of radiation injury patients is essential for determining appropriate diagnostic and therapeutic ...
Initial presentation on January 26, 2026 showcased Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure.
High-dose radiation exposure is known to result in gastrointestinal (GI) acute radiation syndrome injury and currently there are no FDA-approved countermeasures that can treat this condition. To meet ...
(RTTNews) - Pluri Inc. (PLUR), a biotechnology company specializing in cell-based solutions, announced on Monday that it is assessing its readiness to initiate mass production of PLX-R18, a potential ...
CLAREMONT, Calif.--(BUSINESS WIRE)--Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced a partnership valued at up to $119 million ...
INDs Transferred from Statera Biopharma Advance Entolimod for ARS Along Regulatory Pathway and Enable Pursuit of Clinical Trial Program in Neutropenia and Lymphocyte Exhaustion FREMONT, ...
FREMONT, CA / ACCESS Newswire / January 28, 2026 / Tivic Health ® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that it delivered an invited presentation at a ...
Redhill Biopharma Ltd.'s opaganib hydrochloride (ABC-294640) has been selected by the Radiation and Nuclear Countermeasures Program (RNCP), of the National Institute of Allergy and Infectious Diseases ...
Military personnel enter active duty knowing there are risks involved. One risk that affects a small proportion of veterans is illness caused by radiation exposure during service. Most veterans don’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results